- Givosiran, sold
under the
brand name
Givlaari, is a
medication used for the
treatment of
adults with
acute hepatic porphyria.
Givosiran is a
small interfering...
- of
transthyretin mRNA. In 2019, FDA
approved the
second RNAi therapy,
Givlaari (givosiran) used to
treat acute hepatic porphyria (AHP). The
disease is...
- injection,
lipid complex".
Daily Med. 10 May 2021. "Drug
Approval Package:
GIVLAARI (givosiran)Injection". FDA. Gonzalez-Aseguinolaza G (11 June 2020). "Givosiran...
-
commercialization of the
first four RNAi
therapeutic medicines: ONPATTRO,
GIVLAARI, OXLUMO, and LEQVIO. The
fifth RNAi
therapeutic medicine, AMVUTTRA, was...
-
Porphyria Foundation".
Retrieved 2010-03-01. "Alnylam
Announces Approval of
GIVLAARI® (givosiran) in the
European Union for the
Treatment of
Acute Hepatic"...
-
transthyretin mRNA (US and
European approval granted 2018).
Givosiran (
Givlaari) for the
treatment of
adults with
acute hepatic porphyria, administered...
